MedTrace Logo

Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

NCT04809181 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2023-02-21

No results posted yet for this study

Summary

In patients with MRD-positive patients after AML/MDS allogeneic hematopoietic stem cell transplantation, azacytidine combined with venetoclax may be effective in eliminating micro residual diseases, reducing the risk of relapse, and ultimately improving long-term survival.The primary purpose of this study was to explore an effective protocol to reduce the risk of relapse in patients with MRD positive after allogeneic hematopoietic stem cell transplantation for AML/MDS.

Conditions

  • Hematologic Malignancy
  • Stem Cell Transplant Complications

Interventions

DRUG

Azacitidine in Combination With Venetoclax

Azacitidine in combination with venetoclax

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    collaborator OTHER

  • Zhejiang Provincial People's Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Zhejiang Chinese Medical University

    collaborator OTHER

  • Sir Run Run Shaw Hospital

    collaborator OTHER

  • First Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • Ningbo No. 1 Hospital

    collaborator OTHER

  • Yinzhou Hospital Affiliated to Medical School of Ningbo University

    collaborator OTHER

  • Jinhua Central Hospital

    collaborator OTHER

  • Taizhou Hospital

    collaborator OTHER

  • Union hospital of Fujian Medical University

    collaborator OTHER

  • Xiangya Hospital of Central South University

    collaborator OTHER

  • First Affiliated Hospital of Zhejiang University

    lead OTHER

Principal Investigators

  • Yi Luo, M.D. · First Affilaated Hospital of Medical School of Zhejiang University

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-19
Primary Completion
2024-03-19
Completion
2026-03-19

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04809181 on ClinicalTrials.gov